

# David K Wyld

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2166403/publications.pdf>

Version: 2024-02-01

107  
papers

4,452  
citations

279487

23  
h-index

110170

64  
g-index

113  
all docs

113  
docs citations

113  
times ranked

5766  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2004, 350, 351-360.	13.9	2,161
2	Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. <i>Nature Communications</i> , 2018, 9, 3970.	5.8	192
3	Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. <i>Lancet Oncology</i> , The, 2007, 8, 603-612.	5.1	127
4	Detection of colorectal cancer cells in peripheral blood by reverse-transcriptase polymerase chain reaction for cytokeratin 20. , 1998, 79, 288-293.		110
5	Health-Related Quality of Life in Patients With Advanced Colorectal Cancer Treated With Cetuximab: Overall and KRAS-Specific Results of the NCIC CTG and AGITG CO.17 Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 1822-1828.	0.8	106
6	Mapping unmet supportive care needs, quality-of-life perceptions and current symptoms in cancer survivors across the Asia-Pacific region: results from the International STEP Study. <i>Annals of Oncology</i> , 2017, 28, 2552-2558.	0.6	102
7	Prognostic gene expression signature for high-grade serous ovarian cancer. <i>Annals of Oncology</i> , 2020, 31, 1240-1250.	0.6	85
8	Anxiety, depression and quality of life in people with pancreatic cancer and their carers. <i>Pancreatology</i> , 2017, 17, 321-327.	0.5	71
9	Phase I Biodistribution and Pharmacokinetic Study of Lewis X Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers. <i>Clinical Cancer Research</i> , 2009, 15, 6709-6715.	3.2	70
10	Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice. <i>Clinical Cancer Research</i> , 2017, 23, 5789-5801.	3.2	70
11	Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. <i>JAMA Oncology</i> , 2018, 4, 1597.	3.4	68
12	Respiratory bronchiolitis-associated interstitial lung disease secondary to electronic nicotine delivery system use confirmed with open lung biopsy. <i>Respirology Case Reports</i> , 2017, 5, e00230.	0.3	62
13	Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. <i>Journal of Clinical Neuroscience</i> , 2010, 17, 970-974.	0.8	54
14	Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: a pilot study. <i>BMC Cancer</i> , 2011, 11, 389.	1.1	53
15	A tsunami of unmet needs: pancreatic and ampullary cancer patients' supportive care needs and use of community and allied health services. <i>Psycho-Oncology</i> , 2016, 25, 150-157.	1.0	53
16	A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. <i>Investigational New Drugs</i> , 2007, 25, 247-252.	1.2	52
17	Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy. <i>JAMA Network Open</i> , 2021, 4, e2036695.	2.8	49
18	The Median Informs the Message: Accuracy of Individualized Scenarios for Survival Time Based on Oncologists' Estimates. <i>Journal of Clinical Oncology</i> , 2013, 31, 3565-3571.	0.8	43

#	ARTICLE	IF	CITATIONS
19	Central venous Access device SeCurement And Dressing Effectiveness for peripherally inserted central catheters in adult acute hospital patients (CASCADE): a pilot randomised controlled trial. <i>Trials</i> , 2017, 18, 458.	0.7	40
20	A single-blind, randomised controlled trial of StrataXRT <sup>®</sup> – A silicone-based film-forming gel dressing for prophylaxis and management of radiation dermatitis in patients with head and neck cancer. <i>Radiotherapy and Oncology</i> , 2019, 139, 72-78.	0.3	34
21	Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer – A population-based study. <i>Gynecologic Oncology</i> , 2013, 129, 310-317.	0.6	30
22	Describing Patterns of Care in Pancreatic Cancer. <i>Pancreas</i> , 2015, 44, 1259-1265.	0.5	30
23	Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 401-408.	1.0	27
24	Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. <i>British Journal of Cancer</i> , 2010, 103, 597-606.	2.9	25
25	Oncology practitioners <sup>™</sup> perspectives and practice patterns of post-treatment cancer survivorship care in the Asia-Pacific region: results from the STEP study. <i>BMC Cancer</i> , 2017, 17, 715.	1.1	25
26	Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1278-1284.	2.8	25
27	Expression profiling correlates with treatment response in women with advanced serous epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2006, 119, 875-883.	2.3	24
28	Determinants of Outcomes Following Resection for Pancreatic Cancer – a Population-Based Study. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1471-1481.	0.9	24
29	The utility of the implementation science framework – Integrated Promoting Action on Research Implementation in Health Services – (i-PARIHS) and the facilitator role for introducing patient-reported outcome measures (PROMs) in a medical oncology outpatient department. <i>Quality of Life Research</i> , 2021, 30, 3063-3071.	1.5	24
30	Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma. <i>Theranostics</i> , 2020, 10, 4116-4133.	4.6	23
31	A prospective study of the impact of fluorodeoxyglucose positron emission tomography with concurrent non-contrast CT scanning on the management of operable pancreatic and periampullary cancers. <i>Hpb</i> , 2015, 17, 624-631.	0.1	22
32	Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study. <i>Supportive Care in Cancer</i> , 2016, 24, 3589-3599.	1.0	22
33	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 307-320.	1.4	22
34	The effects of a family-centered psychosocial-based nutrition intervention in patients with advanced cancer: the PiCNIC2 pilot randomised controlled trial. <i>Nutrition Journal</i> , 2021, 20, 2.	1.5	22
35	Epidemiological trends of neuroendocrine tumours over three decades in Queensland, Australia. <i>Cancer Epidemiology</i> , 2019, 63, 101598.	0.8	21
36	Factors associated with quality of care for patients with pancreatic cancer in Australia. <i>Medical Journal of Australia</i> , 2016, 205, 459-465.	0.8	20

#	ARTICLE	IF	CITATIONS
37	Equity across the cancer care continuum for culturally and linguistically diverse migrants living in Australia: a scoping review. <i>Globalization and Health</i> , 2021, 17, 87.	2.4	20
38	Medical Costs and Outcomes for Australian Women With Ovarian Cancer: A Patient-Level Analysis Over 2.5 Years. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 757-765.	1.2	19
39	Terminal anticipation: entanglements of affect and temporality in living with advanced cancer. <i>Subjectivity</i> , 2017, 10, 374-392.	0.2	19
40	Association between pancreatic cancer patients' perception of their care coordination and patient-reported and survival outcomes. <i>Palliative and Supportive Care</i> , 2018, 16, 534-543.	0.6	16
41	What is needed by staff to implement PROMs into routine oncology care? A qualitative study with the multi-disciplinary team. <i>European Journal of Cancer Care</i> , 2019, 28, e13167.	0.7	16
42	Chemotherapy in patients with unresected pancreatic cancer in Australia: A population-based study of uptake and survival. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 326-336.	0.7	15
43	PET Imaging Quantifying <sup>68</sup> Ga-PSMA-11 Uptake in Metastatic Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1576-1579.	2.8	15
44	Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of <sup>177</sup> Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and tumors (pNETS, mNETS).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4608-4608.	0.8	15
45	Determinants of survival and attempted resection in patients with non-metastatic pancreatic cancer: An Australian population-based study. <i>Pancreatology</i> , 2016, 16, 873-881.	0.5	14
46	Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test. <i>Journal of Cancer Survivorship</i> , 2019, 13, 495-502.	1.5	14
47	Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma. <i>Gynecologic Oncology</i> , 2011, 120, 179-184.	0.6	12
48	The Social Reception of Women With Cancer. <i>Qualitative Health Research</i> , 2017, 27, 983-993.	1.0	12
49	Perceptions of care and patient-reported outcomes in people living with neuroendocrine tumours. <i>Supportive Care in Cancer</i> , 2018, 26, 3153-3161.	1.0	12
50	First results for Australasian Gastrointestinal Trials Group (AGITG) control net study: Phase II study of <sup>177</sup> Lu-octreotate peptide receptor radionuclide therapy (LuTate PRRT) +/- capecitabine, temozolomide (CAPTEM) for midgut neuroendocrine tumors (mNETs).. <i>Journal of Clinical Oncology</i> , 2020, 38, 604-604.	0.8	12
51	Endocrine aspects of the clinical management of breast cancer - current issues. <i>Endocrine-Related Cancer</i> , 1998, 5, 97-110.	1.6	11
52	Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 350-358.	1.2	11
53	Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: A prospective analysis. <i>Gynecologic Oncology</i> , 2014, 132, 130-136.	0.6	11
54	The Economic Impact on Australian Patients with Neuroendocrine Tumours. <i>Patient</i> , 2020, 13, 363-373.	1.1	11

#	ARTICLE	IF	CITATIONS
55	Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: <sup>177</sup> Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)â€™Final results.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4122-4122.	0.8	11
56	Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e1181-e1187.	1.1	10
57	Responses to a cancer diagnosis: a qualitative patient-centred interview study. <i>Supportive Care in Cancer</i> , 2020, 28, 229-238.	1.0	10
58	The (Co)Production of Difference in the Care of Patients With Cancer From Migrant Backgrounds. <i>Qualitative Health Research</i> , 2020, 30, 1619-1631.	1.0	10
59	Using a Delphi process to determine optimal care for patients with pancreatic cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 105-114.	0.7	9
60	Cancer on the margins: experiences of living with neuroendocrine tumours. <i>Health Sociology Review</i> , 2018, 27, 153-167.	1.7	9
61	Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patients. <i>Supportive Care in Cancer</i> , 2010, 18, 943-949.	1.0	8
62	Taking care of our own: A narrative review of cancer care services-led models of care providing emergent care to patients with cancer. <i>European Journal of Oncology Nursing</i> , 2019, 40, 85-97.	0.9	8
63	The iPROMOS protocol: a stepped-wedge study to implement routine patient-reported outcomes in a medical oncology outpatient setting. <i>BMJ Open</i> , 2019, 9, e027046.	0.8	8
64	Reciprocity, Autonomy, and Vulnerability in Menâ€™s Experiences of Informal Cancer Care. <i>Qualitative Health Research</i> , 2020, 30, 491-503.	1.0	8
65	Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours. <i>Oncotarget</i> , 2020, 11, 2636-2646.	0.8	8
66	Nesidioblastosis as a cause of focal pancreatic <sup>111</sup> In-pentetreotide uptake in a patient with putative VIPoma: another differential diagnosis. <i>Annals of Nuclear Medicine</i> , 2009, 23, 497-499.	1.2	7
67	Biliary Stenting in Patients With Pancreatic Cancer. <i>Pancreas</i> , 2018, 47, 80-86.	0.5	7
68	Supporting patients and carers affected by pancreatic cancer: A feasibility study of a counselling intervention. <i>European Journal of Oncology Nursing</i> , 2020, 46, 101729.	0.9	7
69	Trends in epidemiology, treatment and molecular testing of metastatic colorectal cancer in a realâ€™world multiâ€™institution cohort study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 84-93.	0.7	7
70	â€™My biggest worry now is how my husband is going to copeâ€™: womenâ€™s relational experiences of cancer careâ€™ during illness. <i>Journal of Gender Studies</i> , 2018, 27, 901-913.	1.3	6
71	Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours. <i>Cancer Medicine</i> , 2021, 10, 8405-8411.	1.3	6
72	An analysis of incidental and symptomatic pulmonary embolism (PE) in medical oncology patients. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 243-248.	0.7	5

#	ARTICLE	IF	CITATIONS
73	A case of pulmonary carcinoid in pregnancy and review of carcinoid tumours in pregnancy. <i>Obstetric Medicine</i> , 2017, 10, 142-149.	0.5	5
74	Statistical process control assessed implementation fidelity of patient-reported outcome measures (PROMs) in routine care. <i>Journal of Clinical Epidemiology</i> , 2020, 127, 76-86.	2.4	5
75	Determining the CA19-9 concentration that best predicts the presence of CT-occult unresectable features in patients with pancreatic cancer: A population-based analysis. <i>Pancreatology</i> , 2020, 20, 1458-1464.	0.5	5
76	Our experience of nursing/allied health practitioner led geriatric screening and assessment of older patients with cancer – a highly accessible model of care. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1186-1192.	0.5	5
77	Factors in Randomized Controlled Trials Reported to Impact the Implementation of Patient-Reported Outcome Measures Into Routine Care: Protocol for a Systematic Review. <i>JMIR Research Protocols</i> , 2019, 8, e14579.	0.5	5
78	Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care. <i>Journal of Clinical Medicine</i> , 2019, 8, 1455.	1.0	4
79	Individualising difference, negotiating culture: Intersections of culture and care. <i>Health (United Kingdom)</i> 2021, 10, 0784314.	0.9	4
80	Incidence, survival and stage at diagnosis of small intestinal neuroendocrine tumours in Queensland, Australia, 2001-2015. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 350-358.	0.7	4
81	Resilience and ongoing quality care for cancer clinical trials during COVID-19: Experience from a tertiary hospital in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, , .	0.7	4
82	Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention. <i>JMIR Research Protocols</i> , 2019, 8, e14361.	0.5	3
83	The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose ( <sup>18</sup> F) positron emission tomography positive intermediate grade pancreatic neuroendocrine tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 150-157.	0.7	2
84	Semiquantitative research protocol to explore cancer care workforce perceptions of the health system response to COVID-19 preparations in Southeast Queensland, Australia. <i>BMJ Open</i> , 2021, 11, e044655.	0.8	2
85	Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer. <i>Contrast Media and Molecular Imaging</i> , 2021, 2021, 1-12.	0.4	2
86	Detection of colorectal cancer cells in peripheral blood by reverse transcriptase polymerase chain reaction for cytokeratin 20. <i>International Journal of Cancer</i> , 1998, 79, 288-293.	2.3	2
87	Salvage 177Lu-dotatate therapy in patients with progressive metastatic neuroendocrine tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16212-e16212.	0.8	2
88	Tumor Cystic Necrosis Following Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2018, 43, 186-187.	0.7	1
89	Prospective cohort study of an Australian cancer care services-led model of emergent care. <i>Australian Health Review</i> , 2021, 45, 613-621.	0.5	1
90	The unmet supportive care needs, quality of life, and care experiences of patients with functioning and non-functioning Neuroendocrine tumours (NETs) at early diagnosis. <i>Patient Education and Counseling</i> , 2021, 105, 212-220.	1.0	1

#	ARTICLE	IF	CITATIONS
91	177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with somatostatin-expressing neuroendocrine tumors: A real-world retrospective review of efficacy and safety from an Australian tertiary cancer Center.. Journal of Clinical Oncology, 2021, 39, e16198-e16198.	0.8	1
92	Dietary patterns and attitudes in cancer patients.. Journal of Clinical Oncology, 2018, 36, e22055-e22055.	0.8	1
93	Psychosocial impacts of COVID-19 on oncology workforces: Metro versus regional Australia.. Journal of Clinical Oncology, 2020, 38, 111-111.	0.8	1
94	Factors that influence clinical trial participation by patients with cancer in Australia: a scoping review protocol. BMJ Open, 2022, 12, e057675.	0.8	1
95	Scoping to analyze oncology trial participation in Australia. Seminars in Oncology, 2022, 49, 178-181.	0.8	1
96	Metastatic paraganglioma with extensive bone marrow involvement. Asia-Pacific Journal of Clinical Oncology, 2006, 2, 193-194.	0.7	0
97	Quality of Life and Treatment Response Among Women With Platinum-Resistant Versus Platinum-Sensitive Ovarian Cancer Treated for Progression. Obstetrical and Gynecological Survey, 2014, 69, 257-259.	0.2	0
98	How do cancer care services in Australia take care of their patients when they require emergency care? We need more evidence. Australian Health Review, 2020, 44, 497.	0.5	0
99	P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs).. Journal of Clinical Oncology, 2021, 39, TPS390-TPS390.	0.8	0
100	Psychosocial impacts of COVID-19 upon a diverse Australian oncology workforce: From doctors to ancillary staff.. Journal of Clinical Oncology, 2021, 39, e23016-e23016.	0.8	0
101	Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, k-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC).. Journal of Clinical Oncology, 2012, 30, 3572-3572.	0.8	0
102	Usefulness of medical oncologistsâ€™ estimates of survival time in people with advanced cancer.. Journal of Clinical Oncology, 2012, 30, 9087-9087.	0.8	0
103	Lean thinking: Exploring the volume of overhead and supplementary tasks (OST) in cancer care (CC) in the oncology outpatient encounter (OOE) in two tertiary centres.. Journal of Clinical Oncology, 2016, 34, 6589-6589.	0.8	0
104	P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).. Journal of Clinical Oncology, 2019, 37, TPS539-TPS539.	0.8	0
105	Pretherapeutic 68Ga-DOTATATE PET SUV predictors of survival of radionuclide therapy for metastatic neuroendocrine tumors.. Journal of Clinical Oncology, 2020, 38, 4609-4609.	0.8	0
106	P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).. Journal of Clinical Oncology, 2020, 38, TPS425-TPS425.	0.8	0
107	Emotional impact of COVID-19 preparations on metro and regional cancer workforces in Queensland Australia: "We are all in this together".. Journal of Clinical Oncology, 2020, 38, 44-44.	0.8	0